- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05183737
Effects of Microencapsulated Propolis and Turmeric in Patients With Chronic Kidney Disease
Effects of Supplementation With Microcapsules of Tumeric and Propolis on Inflammatory Markers in Patients on Hemodialysis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The so-called Chronic Non-Communicable Diseases (NCDs) have been increasing in incidence. Among these, one can mention Chronic Kidney Disease (CKD). CKD is considered a public health problem and is characterized by an irreversible syndrome resulting from changes in the function or structure of the kidney, which has a progressive evolution.
Oxidative stress is one of the most potent inducers of inflammation, being an imbalance between the production of reactive oxygen species (ROS) and cellular antioxidant capacity, so that such imbalance can influence the activation of the nuclear factor kB (NF-κB), inflammation-associated interleukins, and tumor necrosis factor alpha 4 (TNF-α), which are promoters of cell damage and organic molecules. Patients with CKD on HD showed increased expression of NF-κB and reduced expression of Nrf2, so it is important to perform studies that propose ways to increase the performance of Nrf2, as well as reduce the activation of NF-κB. the performance of propolis and turmeric.
The study aims to evaluate the effects of supplementation of propolis and turmeric microcapsules on inflammatory markers and clinical parameters in patients with chronic kidney disease undergoing hemodialysis.
Sample calculation was performed using the G-Power 3.1 software, with a test power of 80%, considering the expression of NF-κB as the main outcome, significance level of 5% (two-tailed), effect size of 1, 32. The sample obtained consisted of 34 patients (17 in each group).
The proposed clinical study is a longitudinal randomized and double-blind (randomized controlled trial - RCT) where patients will receive capsules containing microencapsulated turmeric and propolis, twice a day, for 12 weeks. The mixture of microcapsules of propolis and turmeric will be distributed to participants in the form of hard gelatine capsules. The placebo group will receive the same amount of capsules, at the same times, containing gum arabic and corn starch. Randomization will be computerized in a 1:1 ratio.
- Anthropometric assessments, food intake, blood collections will be performed at the beginning of the follow-up and in subsequent consultations;
- The analysis of possible adverse effects will be collected through a separate analysis form;
- The assessment of food intake will be performed through the 3-day 24-hour recall;
- The assessment of nutritional status will be performed using anthropometric data;
- Blood samples will be collected in the morning, after fasting for 12 hours, before the dialysis procedure;
- NF-κB expression will be analyzed by means of peripheral blood nuclear cells (PBMCs) using real-time quantitative polymerase chain reaction (qPCR);
- For the measurement of inflammatory cytokines IL-6 and TNF-α, commercial ELISA kits will be used;
- C-reactive protein (CRP) will be determined by chemiluminescence;
- Lipid peroxidation will be estimated by determining thiobarbituric acid reactive substances (TBARS), including MDA, using the modified Ohkawa method;
- The evaluation of the total antioxidant capacity of the plasma will be determined by ELISA;
The effect of supplementation (∆) on each variable will be defined as the subject of the difference between the variable at the end of supplementation with propolis and turmeric and the value of the variable at the end of placebo administration. Statistical analyzes will be performed using SPSS version 22.0.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 22260050
- Denise Mafra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with stage 5 CKD (GFR < 15 mL/min);
- On hemodialysis for more than 6 months;
- Who have arteriovenous fistula (AVF) as vascular access
Exclusion Criteria:
- Pregnant women;
- Smokers;
- Using antibiotics in the last 3 months;
- Using antioxidant supplements;
- Who have habitual intake of propolis, curcumin and turmeric;
- With autoimmune and infectious diseases, cancer, liver and AIDS (Acquired Immunodeficiency Syndrome)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Microcapsules with turmeric and propolis
Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis
|
Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
|
Placebo Comparator: Placebo Group
Participants will receive microcapsules containing arabic gum and cornstarch with the same weight and characteristics as the intersecting microcapsules
|
Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effects of the supplementation on the expression of transcription factors
Time Frame: 4 months
|
Obtain blood samples to assess the effects of supplementation on biomarkers related to inflammation and antioxidant capacity, such as: erythroid nuclear transcription factor 2 (Nrf2) and nuclear factor Kappa B (NF-κB)
|
4 months
|
The effects of the supplementation on inflammatory cytokines
Time Frame: 4 months
|
Get blood samples to evaluate the supplementation effects on cytokines (IL-6, TNF-α)
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effects of supplementation on CRP levels
Time Frame: 4 months
|
Measure before and after supplementation the levels of C-Reactive Protein (mg/dL)
|
4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Denise Mafra, PhD, Universidade Federal Fluminense
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Disease Attributes
- Renal Insufficiency
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Renal Insufficiency, Chronic
- Inflammation
- Anti-Infective Agents
- Propolis
Other Study ID Numbers
- DeniseMafra13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore
Clinical Trials on Microcapsules with turmeric and propolis
-
Government College of Dentistry, IndoreCompleted
-
University College DublinRecruiting
-
Universidade Federal do ParaCompleted
-
Taipei Medical UniversityUnknownOral MucositisTaiwan
-
University of TalcaHospital Regional de TalcaCompletedDiabetes Mellitus, Type 2
-
Federal University of Minas GeraisCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional...CompletedStreptococcal Infections | Saliva Altered
-
Solvay PharmaceuticalsCompletedPostprandial Bloating | Postprandial Belching | Postprandial EructationUnited States
-
Trabzon Kanuni Education and Research HospitalActive, not recruiting
-
Mashhad University of Medical SciencesCompletedRadiation-induced Mucositis of Oral Mucous MembranesIran, Islamic Republic of